CorrlensCorrlens
Correlate

Correlation Analysis

Alnylam Pharmaceuticals, Inc. vs Johnson & Johnson

ALNY vs JNJ

+0.460

Moderate positive

When one moves up, the other tends to follow.

ALNY logo

Alnylam Pharmaceuticals, Inc.

ALNY

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Market cap 43.8B · 2,500 employees

JNJ logo

Johnson & Johnson

JNJ

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Market cap 580.4B

Apr 9, 2021 — Apr 7, 2026Daily1,253 data pointsStockStockHealthcare

Time Series

Relative Performance

Green: ALNYGray: JNJ36 of 1,253 points (sampled)

Who Moves First

ALNY leads JNJ by 6 days

ALNY tends to move before JNJ.

After testing 13 timing shifts, the strongest relationship was +0.482 (they moved in the same direction).

Do They Crash Together?

Correlation by Market Regime

How these series behave when markets are rising, falling, or diverging. A correlation that holds in drawdowns is very different from one that only works in rallies.

Both Rising

+0.208

13 periods · Return correlation when both series rose

Both Falling

+0.268

9 periods · Return correlation when both series fell

Diverging

-0.845

13 periods · Return correlation when series moved apart

R-Squared

21.2%

Share of variance in one series explained by the other.

Trend Agreement

54.8%

How often both series moved in the same direction period-to-period.

Overlap Quality

1,253

Deep shared window — 1,253 usable pairs.

Significance

p < 0.001

95% CI: [0.416, 0.503]

Scatter

XY Regression

98100200300400497135.5140160180200220240252.6Alnylam Pharmaceuticals, Inc.Johnson & JohnsonData pointsFit (r = 0.46)

Pipeline

Data quality details

Pipeline Summary

1,253 paired data points survived the daily window.

Raw input

1,253

1,254

Normalized

1,253

1,254

Prepared

1,253

1,254

Aligned

1,253

1,253

Invalid removed

0

A: 0 / B: 0

Duplicates removed

0

A: 0 / B: 0

Alignment drops

1

A: 0 / B: 1

Series A

ALNY logo

Alnylam Pharmaceuticals, Inc.

ALNY

Market cap 43.8B · 2,500 employees

Stock · 1,253 raw → 1,253 prepared

Series B

JNJ logo

Johnson & Johnson

JNJ

Market cap 580.4B

Stock · 1,254 raw → 1,254 prepared

Sign agreement

100.0%

How often both values share the same sign.

Zero crossings

25

Estimated crossover points between normalized spreads.

Slope

0.1045

Linear regression slope.

Intercept

144.5813

Linear regression intercept.

Related Extremes

Highest and Lowest Correlated

Saved 4 hours ago · ID: stock-alny-vs-stock-jnj-daily